Infliximab has been shown to be of benefit in the treatment of ulcerative colitis, although long-term colectomy rates remain unknown.
Dr Jakobovits and colleagues from England reviewed the rate of colectomy after infliximab for ulcerative colitis.
The research team identified factors that might predict the need for colectomy.
The team conducted a retrospective cohort study of patients with active ulcerative colitis treated with infliximab between 2000 and 2006.
The primary outcome was colectomy-free survival.
Disease and treatment characteristics and complications were documented.
|Of those avoiding colectomy, 17% sustained a steroid-free remission
|Alimentary Pharmacology & Therapeutics|
The researchers assessed 30 patients treated with infliximab for refractory ulcerative colitis.
The research team noted that 53% came to colectomy a median of 140 days after their first infusion.
There was no difference in colectomy between those receiving infliximab failing intravenous steroids, and out-patients with steroid-refractory ulcerative colitis.
The team found that only 17% achieved a steroid-free remission after a median follow-up of 13 months.
On further analysis, the researchers showed that a younger age at diagnosis of colitis was significantly associated with an increased rate of colectomy.
Dr Jakobovits' team concluded, “Over half the patients studied came to colectomy.”
“Of those avoiding colectomy, only 17% sustained a steroid-free remission.”